Valuation: LOTUS PHARM

Market Cap 97.36L 85.36L 78.69L 73.67L 1.38Cr 92Cr 1.41Cr 9.46Cr 3.66Cr 45Cr 3.66Cr 3.58Cr 157.39Cr P/E 2009
3.88x
P/E 2010 4.84x
Enterprise Value 1.44Cr 1.26Cr 1.16Cr 1.09Cr 2.04Cr 135.67Cr 2.08Cr 14Cr 5.41Cr 67Cr 5.4Cr 5.28Cr 232.51Cr EV / Sales 2009
1.02x
EV / Sales 2010 0.95x
Free-Float
99%
Yield 2009 *
-
Yield 2010 -
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%+1.33%+10.38%+82.31% 4.74TCr
+1.94%+3.91%+54.17%+108.57% 3.55TCr
+0.15%+6.53%-4.15%+42.60% 1.23TCr
+0.19%+2.86%+12.18%+89.10% 1.16TCr
-0.57%+0.38%+36.72%+126.29% 888.1Cr
+0.99%+4.52%+21.27%+44.41% 720.73Cr
+0.86%+2.24%+53.82%-8.96% 691.07Cr
-1.20%-2.67%+25.90%+218.89% 644.5Cr
-3.83%-0.76%-35.52%-3.58% 494.11Cr
Average -0.24%+2.62%+19.42%+77.74% 1.57TCr
Weighted average by Cap. +0.15%+2.86%+23.70%+85.59%

Financials

2009 2010
Net sales 5.78Cr 5.07Cr 4.67Cr 4.38Cr 8.2Cr 545.47Cr 8.37Cr 56Cr 22Cr 269.59Cr 22Cr 21Cr 934.8Cr 7.27Cr 6.37Cr 5.88Cr 5.5Cr 10Cr 685.76Cr 11Cr 71Cr 27Cr 338.92Cr 27Cr 27Cr 1.18TCr
Net income 1.64Cr 1.44Cr 1.33Cr 1.24Cr 2.33Cr 155.01Cr 2.38Cr 16Cr 6.18Cr 77Cr 6.17Cr 6.04Cr 265.65Cr 1.44Cr 1.26Cr 1.17Cr 1.09Cr 2.05Cr 136.07Cr 2.09Cr 14Cr 5.42Cr 67Cr 5.42Cr 5.3Cr 233.2Cr
Net Debt 5.29 4.64 4.28 4.01 7.51 499.38 7.67 51.42 19.9 246.81 19.88 19.44 855.82 4.65 4.07 3.76 3.52 6.59 438.34 6.73 45.14 17.47 216.64 17.45 17.07 751.2
Logo LOTUS PHARM
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
-